Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Hikma Pharmaceuticals : Drugmaker asked Arkansas not to use drug in executions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/21/2017 | 06:56pm CEST

A drugmaker asked Arkansas officials not to purchase its products for executions months before the state accepted a third-party "donation" of potassium chloride as one of three drugs to use in lethal injections, according to letters obtained by The Associated Press.

Fresenius Kabi USA wrote to Department of Correction Director Wendy Kelley and other officials last July saying the company was aware Arkansas wanted to buy drugs to carry out executions and asking the state not to violate contracts between Fresenius and its distributors that forbid the distributors from selling the drugmaker's products for use in capital punishment.

Fresenius has since identified itself as the possible maker of the Arkansas' supply of potassium chloride — which Kelley recently testified she obtained by driving to an undisclosed location to meet an unnamed distributor, who when told about the billing process chose to "donate" it rather than create a record of the sale.

Legal and pharmaceutical experts said the methods Arkansas used to obtain the potassium chloride, midazolam and vecuronium bromide to resume carrying out its first executions since 2005 raise concerns about the state's respect for contracts between private businesses.

Arkansas carried out an execution Thursday using the drugs after the state Supreme Court reversed a judge's order that had halted the use of the vecuronium bromide. The ruling came in an unprecedented lawsuit from drug distributor McKesson Corp., which alleged state officials misled the company when purchasing its supply of vecuronium bromide last July by using a physician's license number that implied the drug would be used only for medically approved purposes.

The state had planned to use the drugs in four double executions over an 11-day period in April. The eight executions would have been the most by a state in such a compressed period since the U.S. Supreme Court reinstated the death penalty in 1976. The state said the executions needed to be carried out before its supply of the sedative midazolam expires on April 30. Three executions were canceled because of court decisions, and court rulings have put at least one other in doubt.

The state has refused to answer questions about the drug suppliers, including whether the Department of Correction received Fresenius' letters, citing a law that keeps the drug sources secret. However, at a court hearing on the McKesson lawsuit, department deputy director Rory Griffin said he did tell a McKesson salesman about the intended purpose of the drug.

A spokeswoman for McKesson didn't immediately return a request for comment Friday. Representatives for Fresenius and Hikma Pharmaceuticals — the parent company for West-Ward, which the AP identified in 2015 as the likely maker of Arkansas' midazolam — said they don't know for sure that the state used their products because Arkansas officials won't answer their questions.

"If the State of Arkansas was able to procure any of our U.S.-manufactured drugs for use in lethal injections despite these controls - which it will not confirm or deny to us - it was not directly from us, nor with our knowledge," Hikma Pharmaceuticals spokeswoman Brooke Clarke wrote. "We have made our objections to the misuse of any of our products for lethal injection known to the governors, attorneys general and departments of correction in every state with capital punishment."

According to Fresenius' July letter, use of its drugs in executions could result in stricter regulations from the European Union, which bans the export of drugs used in lethal injections. Fresenius spokesman Matt Kuhn confirmed that President and CEO John Ducker wrote the letter as well as another sent in 2016 and one sent in recent weeks.

"We would like the Arkansas Department of Correction to destroy or return any product of ours they may have," Kuhn said, adding the company did not have immediate plans for further legal action.

Hikma also wrote letters to the Correction Department last year seeking the return of its drugs.

"We are concerned that placing further restrictions on the distribution of this product to prevent unintended use may ultimately have a number of negative unintended consequences, such as impacting our ability to supply it for doctors and their patients who have a genuine medical need," Hikma wrote in December.

Robert Dunham, executive director of the Death Penalty Information Center, said the McKesson suit marked the first time a company directly asked a court to stop its drugs from being used.

"What McKesson's lawsuit demonstrates is that the secrecy law is not designed to protect the distributors and manufacturers; it's designed to try to prevent them from learning that the state has improperly obtained the drugs," said Dunham, whose nonprofit group opposes the death penalty.

Courts have upheld Arkansas' secrecy law and similar laws in a handful of other states.

Arkansas isn't the first state to be accused of deceptively obtaining execution drugs. Ohio officials allegedly inquired about drugs through its mental health department, and Texas allegedly used a drug registration number for a long-shuttered prison hospital. An assistant attorney general in Arkansas said in a court proceeding in 2015 that the third-party supplier of the state's midazolam agreed to the sale in return for anonymity despite the supplier's contract with the manufacturer forbidding the sale.

One business leader and vocal death penalty opponent found Arkansas' efforts to get around contracts between two private companies to be troubling.

"They suggest the state cares more about the killing of prisoners than it does about the integrity of private contracts — another red flag for any business," Richard Branson, the billionaire founder of the Virgin Group, wrote in a recent blog.

But Arkansas Economic Development Commission Executive Director Mike Preston said he hasn't seen any backlash.

"Among all the companies we've met and spoken to recently not one has brought up anything related to the state's executions," he said.

Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed., source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS
06/01 FTSE flirts with record level though sterling boost fades; Inmarsat jumps
05/26 British shares up 0.34 pct Monday
05/23 HIKMA PHARMACEUTICALS : Participates in 2017 World Economic Forum in Jordan
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
05/17 FTSE breaks nine-day winning streak as miners, British Land fall
05/17 HIKMA PHARMACEUTICALS : to Publish Report on its Alignment with UN Sustainable D..
05/15 British stocks close flat Thursday
05/12 Record close for FTSE as AstraZeneca soars
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/08 Jazz Keeps The Narcolepsy Market Awake
05/12 'MAJOR' REPRIEVE NUMBER TWO : Another Stumble For GlaxoSmithKline's Advair Block..
04/21 JAZZ PHARMACEUTICALS : Recent News Shows Just How Good It Really Is
03/30 GLAXOSMITHKLINE : Delay In Mylan's Advair Generic Is A Helpful Short-Term Boost,..
03/15 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Full Year 2016 Results - ..
Advertisement
Financials ($)
Sales 2017 2 078 M
EBIT 2017 415 M
Net income 2017 223 M
Debt 2017 475 M
Yield 2017 1,53%
P/E ratio 2017 21,52
P/E ratio 2018 15,89
EV / Sales 2017 2,56x
EV / Sales 2018 2,30x
Capitalization 4 850 M
More Financials
Chart HIKMA PHARMACEUTICALS
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 25,4 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Said Samih Taleb Darwazah Chairman & Chief Executive Officer
Khalid Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Ragheb Al-Shakhshir Vice President-Research & Development
Mohammed Ali Khaldoun Al-Husry Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS-16.01%4 850
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results